what are monoclonal antibodies?, differences bw monoclonal and polyclonal ab, briefly about principle and production of mAB, and what are its applications

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Reading File

Finding Sources

I now have comprehensive content. Let me compile the full answer.

Monoclonal Antibodies (mAbs) - A Complete Overview

1. What Are Monoclonal Antibodies?

Monoclonal antibodies (mAbs) are homogeneous, identical antibody molecules all derived from a single B-cell clone, recognizing one specific epitope on an antigen. The term "monoclonal" means they originate from one ("mono") cell line ("clone").

They were first produced in 1975 by Georges Köhler and César Milstein, who fused immune spleen cells with immortal myeloma cells to produce hybrid cell lines (hybridomas) that could proliferate indefinitely and secrete antibody of a predefined specificity. This work earned them the 1984 Nobel Prize in Physiology/Medicine.

Key characteristics:

Recognize a single epitope (one specific binding site)
All molecules are structurally identical - same isotype, same antigen-binding site
Can be produced in unlimited quantities from a stable cell line
Highly consistent affinity and specificity between batches
Janeway's Immunobiology 10e, p. 828
Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 3287

2. Monoclonal vs. Polyclonal Antibodies

Feature	Monoclonal Antibody	Polyclonal Antibody
Origin	Single B-cell clone	Multiple B-cell clones
Epitope specificity	Single epitope	Multiple epitopes on the same antigen
Homogeneity	Completely uniform	Mixture of different antibody molecules
Affinity	Fixed, defined	Variable (mixture of high and low affinity)
Avidity	Lower (single epitope)	Higher (multi-epitope binding)
Cross-reactivity	May cross-react with same epitope on different antigens	Less likely to miss an antigen
Batch-to-batch consistency	Identical - unlimited supply	Each antiserum is different, even in genetically identical animals
Production	Hybridoma or recombinant technology	Simple immunization of an animal
Precipitation/agglutination	Weaker - single epitope creates weak lattice	Stronger - multi-epitope forms better immune complexes
Volume available	Unlimited	Limited

Key insight from Janeway's: "Each antiserum is different from all other antisera, even if raised in a genetically identical animal using the identical preparation of antigen. Antisera can be produced in only limited volumes, and thus it is impossible to use the identical serological reagent in a long or complex series of experiments." mAbs were developed specifically to overcome these limitations.

A polyclonal antibody has stronger avidity to a complex antigen because it binds multiple epitopes simultaneously, while a single mAb recognizes only one epitope. However, mAbs have superior analytical precision - they can distinguish isoenzymes, protein subtypes, and conformational changes at the molecular level.

Janeway's Immunobiology 10e, p. 827
Henry's Clinical Diagnosis and Management, p. 3282

3. Principle and Production of mAbs

Principle

The core challenge: antibody-producing B cells (plasma cells) are mortal and die after a few days in culture. Myeloma (plasma cell tumor) cells are immortal but don't make the desired antibody. The solution - fuse them to combine both properties.

The resulting hybridoma cell has:

From the B cell: ability to make specific antibody
From the myeloma: ability to grow indefinitely in culture

Production Steps (Köhler-Milstein Method)

Monoclonal antibody production - hybridoma technique

Step 1 - Immunization: A mouse is immunized with the target antigen. An intravenous booster is given 3 days before sacrifice to maximize the population of antigen-specific spleen cells secreting antibody.

Step 2 - Cell Fusion: Spleen cells are mixed with myeloma cells (specially selected to: a) produce no antibody themselves, b) lack the enzyme HGPRT - hypoxanthine-guanine phosphoribosyltransferase). Cell fusion is induced using polyethylene glycol (PEG), creating hybridoma cells.

Step 3 - HAT Selection: The mixture is transferred to HAT medium (hypoxanthine-aminopterin-thymidine):

Unfused myeloma cells: die (lack HGPRT, can't use the salvage pathway in aminopterin-blocked medium)
Unfused spleen cells: die naturally (finite lifespan)
Only hybridoma cells survive (get HGPRT from spleen cell, immortality from myeloma cell)

Step 4 - Screening and Cloning: Hybridomas are diluted to single cells (limiting dilution). Individual clones are screened for production of antibody with the desired specificity.

Step 5 - Bulk Culture: The selected hybridoma clone is expanded in bulk culture to produce large quantities of the monoclonal antibody.

Janeway's Immunobiology 10e, p. 828

Humanization of mAbs

Early mouse-derived mAbs caused HAMA (Human Anti-Mouse Antibody) reactions when used therapeutically. This led to progressive engineering:

Chimeric mAbs (-ximab): Human Fc + mouse variable (Fv) domains (e.g., rituximab)
Humanized mAbs (-zumab): Human IgG scaffold with only mouse CDRs inserted (e.g., trastuzumab)
Fully human mAbs (-umab): Entirely human sequence - produced via phage display, transgenic mice, or recombinant cloning of human plasma cell genes (e.g., adalimumab)

The suffix "-mab" in drug names always signals a monoclonal antibody. The preceding morpheme indicates its origin/engineering.

Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 3853

Phage Display (Alternative to Hybridoma)

Antibody V-region genes are fused to bacteriophage coat protein genes. Phages expressing antigen-specific binding domains are isolated by affinity selection. This method eliminates the need for immunization and is now the main method for producing fully human mAbs. Greg Winter received the Nobel Prize (2018) for this concept.

4. Applications of Monoclonal Antibodies

A. Cancer Therapy

This is currently the largest application - over 40 mAb-based drugs are FDA-approved for cancer treatment. Mechanisms include:

Blocking growth factor receptors - e.g., trastuzumab (Herceptin) blocks HER2/ErbB2, cetuximab blocks EGFR
Recruiting immune cells - ADCC (antibody-dependent cellular cytotoxicity) via Fc receptor engagement on NK cells/macrophages
Complement activation - CDC (complement-dependent cytotoxicity)
Checkpoint inhibitors - Anti-PD-1/PD-L1 (pembrolizumab, nivolumab), anti-CTLA-4 (ipilimumab) - restore T cell anti-tumor activity
Antibody-drug conjugates (ADCs) - mAb carries cytotoxic payload (toxin or radionuclide) directly to tumor cells

Goodman & Gilman's, p. 3851

B. Autoimmune and Inflammatory Diseases

Anti-TNF-α: infliximab, adalimumab (rheumatoid arthritis, Crohn's disease, psoriasis)
Anti-IL-6: tocilizumab (rheumatoid arthritis)
Anti-CD20: rituximab (depletes B cells in autoimmune disease and B-cell lymphoma)
Anti-IgE: omalizumab (severe asthma)
Anti-IL-17/23: secukinumab, ustekinumab (psoriasis, psoriatic arthritis)

C. Diagnostics and Laboratory Testing

Immunoassays (ELISA, RIA, chemiluminescence): mAbs provide highly reproducible, specific assays for hormones, tumor markers, drugs, pathogens
Flow cytometry: CD marker identification of cell types (CD4, CD8, etc.)
Immunohistochemistry/immunofluorescence: Tissue diagnosis in pathology
Tumor markers: e.g., CA 19-9 mAb detects carbohydrate epitopes shared across tumor-related molecules
Pregnancy tests, cardiac troponin assays, infectious disease rapid tests - all rely on mAb technology

"Monoclonal antibody technology has allowed the development of extremely useful and nearly ideal immunoassay systems for clinical laboratory testing." - Henry's Clinical Diagnosis

D. Transplantation

Anti-rejection therapy: Anti-CD25 (basiliximab) blocks IL-2 receptor on T cells
T-cell depletion: Anti-thymocyte antibodies used in conditioning regimens

E. Infectious Diseases

Palivizumab: Anti-RSV mAb for prophylaxis in high-risk infants
SARS-CoV-2 neutralizing antibodies: Used during COVID-19 pandemic
Passive immunotherapy against HIV, Ebola, and other pathogens

F. Ophthalmology

Anti-VEGF mAbs: bevacizumab, ranibizumab - treat wet age-related macular degeneration and diabetic retinopathy by blocking neovascularization

G. Cardiovascular

Abciximab: Anti-GPIIb/IIIa - prevents platelet aggregation during coronary intervention
PCSK9 inhibitors: evolocumab, alirocumab - lower LDL cholesterol

H. Research Tools

Western blotting, ELISA development, cell sorting, receptor characterization, drug target validation - mAbs are indispensable research reagents across all of biomedical science

Summary: Monoclonal antibodies represent one of the most significant biotechnological advances in medicine. Derived from a single B-cell clone via hybridoma technology (or modern recombinant methods), they offer unmatched specificity and consistency compared to polyclonal antisera. Their applications now span virtually every area of medicine - from highly sensitive lab diagnostics to life-saving cancer immunotherapies.

This is a shared conversation. Sign in to Orris to start your own chat.